Published at MushroomRevival.com
Click here to hear podcast.
Today we have the pleasure of speaking with Josh Bartch, the CEO of Mydecine, a research & development company with a special interest in psilocybin and psychoactive treatments. We discuss the origins of their work, their team, and current research and practices in the field.
Click here to hear podcast.
Topics covered:
- Mydecine’s mission and commitment to human benefit via fungal discovery
- Psilocybin treatment for PTSD and other mental health concerns
- Machine-learning based drug discovery
- Formulation and commercialization of psychedelic therapeutics
- The deficiencies in chemical compounds in psilocybe mushrooms
- Varietals of psilocybin-containing mushrooms
- Collaborative and intern opportunities at Mydecine’s facilities
- Describing new compounds in functional mushrooms
- Bureaucracy of importing and researching psychedelic mushrooms
- Bioavailability of psilocybin
- Managing ethical clinical research